Alpha-Ketoglutarate Longevity
TL;DR
AKG is biologically plausible as a longevity compound — it inhibits mTOR, induces autophagy, and supports collagen synthesis — and has strong lifespan data in C. elegans and mice. However, no completed independent RCT confirms any AKG longevity benefit in humans. The only human longevity evidence is one open-label, industry-affiliated cohort study (Demidenko 2021) reporting ~8-year DNAm age reduction. This result requires independent replication before it can be treated as credible. The ABLE trial (double-blind placebo-controlled RCT of CaAKG 1g/day, n=120) is the gating data point and should be characterized as pending, never as positive or negative.
Key practical flag for Vitals users: AKG is simultaneously marketed as an mTOR inhibitor (longevity) and a muscle-builder (mTOR activation). These are mechanistically contradictory claims. The evidence does not resolve this tension. Age-dependent rationale is strongest for adults 40+ where endogenous AKG declines.
Why it matters for Vitals
- Biomarker tracking: If a Vitals user is supplementing with AKG, reasonable trackers include IL-6, TNF-α, CRP (inflammatory markers), fasting insulin/HOMA-IR, and grip strength as a functional proxy — these are the primary endpoints of the ABLE trial
- mTOR paradox: Users seeking longevity (mTOR down) and muscle (mTOR up) have conflicting goals that AKG cannot resolve simultaneously
- Age dependency: Rationale for AKG supplementation is essentially absent in younger adults; net benefit is highest in middle-aged and older adults where endogenous AKG declines
- Coaching implication: Do not make AKG longevity claims to Vitals users without disclosing evidence quality; wait for ABLE results before treating this as settled
What the current evidence actually shows
Evidence (source-backed)
| System | Evidence | Grade | Confidence |
|---|---|---|---|
| C. elegans lifespan | ~50% median lifespan extension, AMPK/HLH-30 dependent | A | High |
| Mouse lifespan | CaAKG 1% w/w diet extended lifespan, females > males | A | Positive; generalizability open |
| Collagen synthesis | Direct cosubstrate for prolyl hydroxylase | A | Mechanistically sound; human skin data thin |
| mTOR inhibition | AMPK-mediated, indirect; potency unestablished in humans | B | Plausible; dose translation unknown |
| Human longevity | None — no completed independent RCT | Gap | N/A |
| DNAm age reversal | Single industry cohort (n=42, Demidenko 2021) | C | Requires independent replication |
| Short-term safety | OKG 10g/day acceptable up to several weeks | B | Not generalizable to typical supplement doses |
| Long-term safety | Unknown | Gap | N/A |
Projection (not source-backed)
- AKG supplementation likely supports mitochondrial anaplerosis in older adults — plausible but not measured
- Sustained-release CaAKG likely produces more continuous exposure than immediate-release — mechanistically coherent, unproven clinically
- Anti-inflammatory effect in humans at 1g/day — extrapolated from ABLE primary endpoints, not yet reported
mTOR Paradox — Critical Surfacing Point
AKG is simultaneously marketed as:
- An mTOR inhibitor for longevity (anti-aging framing)
- A muscle-building supplement (anabolic framing)
These are mechanistically contradictory. mTOR activation is required for muscle protein synthesis (MPS). mTOR inhibition suppresses MPS. The anaplerotic muscle benefit (replenishing Krebs cycle intermediates to support MPS) is theoretically possible but has not been demonstrated in humans at longevity doses.
If the primary goal is longevity (mTOR down): AKG is theoretically coherent. If the primary goal is muscle rebuilding: AKG’s mTOR effect is counterproductive. The evidence does not resolve this tension. Do not present AKG as doing both.
The ABLE Trial — What It Is and Why It Is the Gating Data Point
The ABLE trial (double-blind, placebo-controlled RCT of CaAKG 1g/day sustained-release × 6 months, n=120) is the only properly designed independent study of AKG for longevity endpoints in humans. Its primary endpoints are inflammatory markers (IL-6, TNF-α, CRP) and physical function.
Why it gates all AKG longevity claims:
- All human longevity evidence for AKG currently rests on one open-label, industry-affiliated cohort study
- ABLE is the first independent, blinded, placebo-controlled test
- Always characterize as pending — never as positive or negative
- As of April 2026, trial status is unknown; results have not been confirmed published
If ABLE is positive: first independent RCT confirmation of AKG biological activity in humans. If ABLE is null or negative: human longevity evidence collapses back to the single Demidenko industry cohort.
Demidenko 2021 — What to Say and What Not to Say
Do say: “One open-label cohort study (n=42, 8-year follow-up) reported ~8-year reduction in Horvath DNAm clock with CaAKG 1g/day sustained-release. This is a hypothesis-generating signal from an industry-affiliated study that requires independent replication.”
Do NOT say: “AKG reverses biological age by 8 years” or present this as established fact.
Critical limitations of Demidenko 2021:
- Open-label, self-selected participants — no placebo control
- No pre-registered analysis plan
- Industry-affiliated (Ponce de Leon Health / Rejuvant); several authors on advisory board
- p=6.5e-12 — statistical significance is extraordinary and requires extraordinary replication
- n=42 — very small for such a large effect estimate
Source: PMID: 33706561
Formulation Notes (Practical)
| Form | Research Use | Commercial | Notes |
|---|---|---|---|
| CaAKG sustained-release | Demidenko 2021, ABLE trial | Rejuvant (Ponce de Leon) | Most defensible; used in all human trials |
| CaAKG immediate-release | Research | Various | Inferior plasma kinetics vs. SR |
| Free acid AKG | Limited | Various | Aqueous dilution improves absorption |
| DMK (dimethyl ketoglutarate) | In vitro only | Rare | Superior cell penetration in vitro; no human data |
Commercial AKG supplements are not FDA-regulated for quality or dose accuracy. Batch-to-batch variability is a real-world concern not captured in research literature.
Comparison to Other Longevity Compounds
| Compound | Human Longevity Evidence | Vitals Verdict |
|---|---|---|
| Rapamycin | Mouse data strongest of any pharma; human transplant/oncology safety data | More evidence-advanced than AKG; mTOR inhibition direct and potent |
| Metformin | TAME (pending), MILES completed, Bannister observational | Most evidence-advanced AMPK activator for human longevity |
| NAD+ precursors (NMN, NR) | Multiple human trials; increased NAD+, some metabolic benefits | More human trial data than AKG; neither has large RCT longevity outcomes |
| AKG | Single industry cohort | Least human evidence of the group; wait for ABLE |
Risks and Uncertainty
- Long-term safety (>12 months): Completely uncharacterized in healthy adults
- Drug interactions: Unknown
- Cancer risk: mTOR inhibition protective in some cancers; contraindicated in others — no human safety data in oncological populations
- CKD populations: AKG metabolism may differ; caution warranted
- No recommended evidence-backed dose for longevity — 1g/day CaAKG SR is the research dose, not an established efficacy dose
Algorithm Hook
AKG Longevity Evidence Assessment
- Age < 40 → Not recommended (no deficiency state in young adults)
- Goal = muscle building → Not recommended (mTOR inhibition contradicts MPS)
- Goal = longevity, age 40+ → Wait for ABLE trial; evidence level = preliminary
- Any longevity claim to Vitals user → Disclose evidence quality; never cite Demidenko as proof
Related notes
- Alpha-Ketoglutarate — broader AKG hub (bone health, T-cell metabolism, HIF-1α, gut microbiome, neuroprotection)
- Vitals Knowledge Map — vault entry point
- Rapamycin — stronger-evidence mTOR longevity compound
- Metformin — more evidence-advanced AMPK longevity compound
Last updated: 2026-04-20 | Batch: 44 | Source: skills/knowledge-base/alpha-ketoglutarate-longevity/alpha-ketoglutarate-longevity.md